Evaxion Biotech (EVAX) has released an update.
Evaxion Biotech has announced positive pre-clinical results for their novel EVX-B2 mRNA vaccine candidate against Gonorrhea, confirming the effectiveness of their AI-Immunology platform. The vaccine, which has been shown to trigger a targeted immune response leading to the elimination of the bacteria, could be a major advancement as no current vaccine exists for Gonorrhea. These findings, presented at the 18th Vaccine Congress, also highlight the platform’s versatility in vaccine delivery methods.
For further insights into EVAX stock, check out TipRanks’ Stock Analysis page.
